Agilent Technologies’ SureSelect XT Human Methyl-Seq target-enrichment system is designed for epigenetic research into DNA methylation sites.
The assay combines the company’s SureSelect target-enrichment platform with
bisulfite sequencing, the standard for DNA methylation research and the
first comprehensive discovery system. This enables sequence coverage of only
the most relevant regions for epigenetic studies, including those associated
with a wide range of disorders. The system allows researchers to analyze
over 3.7 million individual CpG dinucleotide sequences for their methylation
state. The system targets promoters, canonical CpG islands, and the more
recently described "shores" and "shelves" found up to 4 kilobase pairs on
either side of CpG islands.
This Product is made by:
Agilent Technologies is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. Agilent has two primary business segments: Bio-Analytical Measurement and Electronic Measurement. The company has 19,600 employees and serves customers in more than 110 countries. Agilent had revenue of $5.8B in fiscal year 2008.